HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA TSE Bovine Gelatin Guidance Revisions Recommended By Panel

This article was originally published in The Rose Sheet

Executive Summary

FDA should clarify its recommendations to industry about safe sources of bovine bone gelatin for use in cosmetics, dietary supplements and drugs, a majority of the agency's Transmissible Spongiform Encephalopathies Advisory Committee agreed at a July 17 meeting in Bethesda, Md

You may also be interested in...



U.S. Cosmetic Products Safe From BSE-Infected Cow – FDA

Cosmetics manufactured in the U.S. are highly unlikely to be contaminated by rendered products from the cow in Washington state that tested positive for bovine spongiform encephalopathy last month, according to FDA

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel